NewAmsterdam Pharma Co N.V. (NAMS) Institutional Ownership & Insider Trading

195 institutions reported holding NewAmsterdam Pharma Co N.V. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 43 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

NAMSNewAmsterdam Pharma Co N.V.Follow NAMS — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 2.4B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 11 Nov, in 18 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

195 institutions held —% of the shares. Across filers that reported both quarters, shares held changed -1.8%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	195	122	-1.8%	67	41	47	17
Mar 26	168	123	+3.6%	57	17	49	32
Dec 25	182	119	-2.6%	47	48	49	8
Sep 25	133	122	+4.9%	44	18	39	13
Jun 25	130	116	+4.7%	54	24	28	17
Mar 25	126	111	+12.8%	49	22	30	28
Dec 24	130	99	+23.6%	41	40	30	14
Sep 24	100	77	+6.9%	43	20	15	9

NewAmsterdam Pharma Co N.V. — questions

Who owns NewAmsterdam Pharma Co N.V. stock?: 195 institutions reported NewAmsterdam Pharma Co N.V. shares in 13F filings for the quarter ended 2026-06-30. The largest: Frazier Life Sciences Management, L.P. (15.1%), Capital World Investors (10.2%), FMR LLC (8.7%).
Are NewAmsterdam Pharma Co N.V. insiders buying or selling?: 43 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from NewAmsterdam Pharma Co N.V.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.